Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy.
Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy.
Expert Rev Clin Pharmacol. 2020 Dec 15;:
Authors: Sung WWY, Chow JCH, Cho WCS
PMID: 33322961 [PubMed - as supplied by publisher]
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research